Table 3.

Proportion of subjects showing ≥4-fold increase in antibody titer from baseline for each serotype and time point

Vaccine, serotype, and group	No. (%) of subjects achieving ≥4-fold increase in titer at postvaccination wk:
	1	2	4	6
Influenza virus
A/California/7/2009 (H1N1)-like strain
Secukinumab	9/25 (36)	19/25 (76)	17/25 (68)	16/25 (64)
Control	13/25 (52)	20/25 (80)	20/25 (80)	20/25 (80)
A/Perth/16/2009 (H3N2)-like strain
Secukinumab	4/25 (16)	20/25 (80)	20/25 (80)	19/25 (76)
Control	7/25 (28)	19/25 (76)	18/25 (72)	19/25 (76)
B/Brisbane/60/2008
Secukinumab	3/25 (12)	18/25 (72)	17/25 (68)	18/25 (72)
Control	9/25 (36)	21/25 (84)	19/25 (76)	19/25 (76)
Meningitis
MenC (strain C11)
Secukinumab	8/25 (32)	20/25 (80)	19/25 (76)	16/25 (64)
Control	10/25 (40)	19/25 (76)	18/25 (72)	18/25 (72)